Projects per year
Personal profile
Personal profile
Dr. Ganguly is a board-certified hematologist specializing in the clinical care and research of hematological malignancies, cellular therapeutics, and bone marrow transplantation. Dr. Ganguly was a A. Drue Jennings endowed professor of medical oncology at the University of Kansas Cancer Center in Westwood, Kansas where he was also the Deputy Director of the Division of Hematological Malignancies and Cellular Therapeutics, the Associate Director of Blood and Marrow Transplantation Program, and the Director of Lymphoma and Myeloma Program.
Dr. Ganguly received his undergraduate degree from Calcutta Medical College and his medical degree from the Department of Internal Medicine, Post Graduate, Institute of Medical Education and Research in India. Additionally, he completed his residency in internal medicine and fellowship in hematology at Baylor College of Medicine and concluded another fellowship in bone marrow transplantation at Baylor College of Medicine, Center for Cell and Gene Therapy.
External positions
Professor of Clinical Medicine, Weill Cornell Medical College
May 1 2022 → …
Research Area Keywords
- Cancer
Fingerprint
Dive into the research topics where Siddhartha Ganguly is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Phase 2 study evaluating rapcabtagene autoleucel in participants with severe active GPA or MPA
Kazzaz, S. (PI), Ganguly, S. (Key Personnel), Guevara, M. (Key Personnel), Monga, K. (Key Personnel), Pingali, S. R. (Key Personnel) & Shroff, S. (Key Personnel)
10/29/25 → …
Project: Clinical Trial
-
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects with Non-Oncology Plasma Cell-Related Diseases
Liao, B. (PI), Ganguly, S. (Key Personnel), Greene, E. P. (Key Personnel) & Shroff, S. (Key Personnel)
5/12/25 → …
Project: Clinical Trial
-
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma
Ganguly, S. (PI), Burns, E. A. (Key Personnel), Heslop, H. (Key Personnel), Mai, H. P. (Key Personnel), Pingali, S. R. (Key Personnel) & Shah, S. (Key Personnel)
1/28/25 → …
Project: Clinical Trial
-
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia
Shah, S. (PI), Abanonu, C. (Key Personnel), Burns, E. A. (Key Personnel), Ganguly, S. (Key Personnel), Mai, H. P. (Key Personnel) & Pingali, S. R. (Key Personnel)
10/25/24 → …
Project: Clinical Trial
-
Phase IB/II Study Combining All-Trans Retinoic Acid (ATRA) with Carfilzomib Based Therapy in Plasma Cell Myeloma Patients Refractory to Carfilzomib
Pingali, S. R. (PI), Abanonu, C. (Key Personnel), Burns, E. A. (Key Personnel), Ganguly, S. (Key Personnel), Guan, J. (Key Personnel), Mai, H. P. (Key Personnel), Mathur, S. (Key Personnel), Shah, S. (Key Personnel) & Yi, Q. (Key Personnel)
7/29/24 → …
Project: Clinical Trial
-
Long-term outcomes of light chain amyloidosis patients receiving heart transplant: A single-center experience
Patel, K., Tu, Z. H., Yuen, C., Ganguly, S., Yun, A. N., Gorthi, J. R., Trachtenberg, B. H., Guha, A., Kassi, M., Kim, J., Yousefzai, R., Baker, K., Rice, L., Kamble, R. T., Adrogue, H. E., Suarez, E. E., Ghobrial, M., Saharia, A., Mobley, C. M. & Victor, D. W. & 4 others, , Aug 2025, In: JHLT Open. 9, 100328.Research output: Contribution to journal › Article › peer-review
Open Access -
Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study
Akhtar, O. S., Oloyede, T., Brazauskas, R., Afrough, A., Hashmi, H., Sidana, S., Ahmed, N., Bye, M., Hansen, D., Ferreri, C., Dhakal, B., Dhanda, D., Harrison, M., Kitali, A., Landau, H., Mirza, A. S., Patel, J., Patwardhan, P., Qazilbash, M. & Patel, K. & 7 others, , Apr 8 2025, In: Blood Advances. 9, 7, p. 1587-1592 6 p.Research output: Contribution to journal › Letter › peer-review
Open Access -
Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy
Mercadal, S., Ahn, K. W., Allbee-Johnson, M., Ganguly, S., Geethakumari, P. R., Hong, S., Malone, A., Murthy, H., Pawarode, A., Sica, A. R., Solh, M., Ustun, C., Shadman, M., Sauter, C. S., Hamadani, M., Herrera, A. F. & Lee, C. J., Jan 2025, In: Haematologica. 110, 1, p. 218-221 4 p.Research output: Contribution to journal › Letter › peer-review
Open Access5 Scopus citations -
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma
Sidana, S., Ahmed, N., Akhtar, O. S., Brazauskas, R., Oloyede, T., Bye, M., Hansen, D., Ferreri, C., Freeman, C. L., Afrough, A., Anderson, L. D., Dhakal, B., Dhanda, D., Gowda, L., Hashmi, H., Harrison, M. J., Kitali, A., Landau, H., Mirza, A. S. & Patwardhan, P. & 6 others, , Jul 10 2025, In: Blood. 146, 2, p. 167-177 11 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers
Qian, J., Wang, Q., Xiao, L., Xiong, W., Xian, M., Su, P., Yang, M., Zhang, C., Li, Y., Zhong, L., Ganguly, S., Zu, Y. & Yi, Q., Jan 24 2024, In: Journal for immunotherapy of cancer. 12, 1, e008145.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations